MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
The four-year Government Funded Roadmap for a National Targeted Skin Cancer Screening Program commenced in March 2025. Read the 6-month update on progress so far.
Kim Dowling is a Senior Clinical Data Manager at Melanoma Institute Australia (MIA). Read on to learn about Kim's role, what she loves about her job, plus a few fun facts about her!
Researchers have reported results from an international clinical trial assessing alternative treatment options for lentigo maligna - a non-invasive condition that commonly occurs on sun-exposed areas, particularly the face.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
MIA Bioinformatician Jayden Beckwith answered questions on his impactful research, what he loves about his work, and more on his life outside of work, from hidden talents to a quote he holds dear.
Our amazing community has recently been busy lacing up their runners, going alcohol-free, celebrating milestones, and honouring loved ones, all to support MIA's goal of zero deaths from melanoma! Read more about their efforts.
Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.
